Observations placeholder
Royal jelly and the menopause
Identifier
005346
Type of Spiritual Experience
Background
A description of the experience
J Ethnopharmacol. 2005 Oct 3;101(1-3):215-20. Royal jelly has estrogenic effects in vitro and in vivo. Mishima S, Suzuki KM, Isohama Y, Kuratsu N, Araki Y, Inoue M, Miyata T. Nagaragawa Research Center, API Co., Ltd., 692-3 Nagara, Gifu 502-0071, Japan. mishima-satoshi@api3838.co.jp
Royal jelly (RJ) from honeybees (Apis mellifera) is traditionally thought to improve menopausal symptoms.
The potential estrogenic activities of RJ were investigated using various approaches. RJ competed for binding of 17beta-estradiol to the human estrogen receptor alpha and beta but its affinities were weak compared with diethylstilbestrol and phytoestrogens. The reporter gene expression assays suggested that 0.1-1 mg/ml RJ activated estrogen receptors, leading to enhanced transcription of a reporter gene through an estrogen-responsive element. 1 mg/ml RJ stimulated the mRNA expression of estrogen-responsive pS2 and vascular endothelial growth factor (VEGF) by increasing gene transcription in MCF-7 cells.
Treatment with RJ at concentrations ranging from 0.5 to 1 mg/ml enhanced MCF-7 cell proliferation, but concomitant treatment with 1 microM tamoxifen blocked this effect.
In vivo studies using ovariectomized rats showed that 17beta-estradiol (20 mg/kg, s.c.) treatment restored VEGF expression in both uterus and brain, whereas RJ (1 g/kg, s.c.) restored it in uterus but not in brain.
These findings provide evidence that RJ has estrogenic activities through interaction with estrogen receptors followed by endogenous gene expressions.
PMID: 15946813